2. Search Result
Search Result
Results for "

Cytarabine

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13605
    Cytarabine
    50+ Cited Publications

    Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy Apoptosis Endogenous Metabolite Orthopoxvirus Infection Cancer
    Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.
    Cytarabine
  • HY-13605S
    Cytarabine-d2

    		DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy Apoptosis Endogenous Metabolite Infection Cancer
    Cytarabine-d2 is the deuterium labeled Cytarabine. Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV[1][2].
    Cytarabine-d2
  • HY-115740A
    Cytarabine triphosphate trisodium

    Ara-CTP trisodium

    		 DNA/RNA Synthesis Cancer
    Cytarabine triphosphate (Ara-CTP) trisodiu, an active metabolite of Cytarabine, is a competitive inhibitor of DNA synthesis. Intracellular Cytarabine triphosphate trisodiu levels can be used to predict chemosensitivity of leukemic blasts to Cytarabine .
    Cytarabine triphosphate trisodium
  • HY-13605A
    Cytarabine hydrochloride
    50+ Cited Publications

    Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy Infection Cancer
    Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.
    Cytarabine hydrochloride
  • HY-13605R
    Cytarabine (Standard)

    		DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy Apoptosis Endogenous Metabolite Orthopoxvirus Infection Cancer
    Cytarabine (Standard) is the analytical standard of Cytarabine. This product is intended for research and analytical applications. Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.
    Cytarabine (Standard)
  • HY-115740
    Cytarabine triphosphate

    Ara-CTP

    		 DNA/RNA Synthesis Cancer
    Cytarabine triphosphate (Ara-CTP), an active metabolite of Cytarabine, is a competitive inhibitor of DNA synthesis. Intracellular Cytarabine triphosphate levels can be used to predict chemosensitivity of leukemic blasts to Cytarabine .
    Cytarabine triphosphate
  • HY-W344074
    Cytarabine 5’-monophosphate

    		DNA/RNA Synthesis Drug Metabolite Cancer
    Cytarabine 5′-monophosphate is a metabolite of the nucleoside analog Cytarabine (HY-13605), catalyzed by deoxycytidine kinase. Cytarabine 5′-monophosphate is incorporated into DNA by DNA polymerase α, which reduces the rate of DNA synthesis. At a concentration of 15 mM, Cytarabine 5′-monophosphate inhibits nuclear and mitochondrial DNA replication in Saccharomyces cerevisiae (S. cerevisiae). Additionally, Cytarabine 5′-monophosphate (3.5-75.1 mg/kg) improves survival in leukemia mice (L1210 mice). Cytarabine 5′-monophosphate can be used in cancer research .
    Cytarabine 5’-monophosphate
  • HY-W654127
    Cytarabine-13C3 5'-monophosphate

    		Isotope-Labeled Compounds Others
    Cytarabine- 13C3 5'-monophosphate is 13C labeled Cytarabine 5’-monophosphate .
    Cytarabine-13C3 5'-monophosphate
  • HY-106349
    Fosteabine

    Cytarabine ocfosfate; YNK 01

    		 Nucleoside Antimetabolite/Analog Cancer
    Fosteabine is an oral and proagent analogue of cytarabine which is resistant to deoxycytidine deaminase.
    Fosteabine
  • HY-W654126
    Cytarabine-13C3

    Cytosine β-D-arabinofuranoside--13C3; Cytosine Arabinoside--13C3; Ara-C-13C3

    		 Isotope-Labeled Compounds Others
    Cytarabine- 13C3 (Cytosine β-D-arabinofuranoside- 13C3) is 13C labeled Cytarabine .
    Cytarabine-13C3
  • HY-16445
    Sapacitabine

    CS682; CYC682

    		 Nucleoside Antimetabolite/Analog Cancer
    Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
    Sapacitabine
  • HY-154971
    Ara-SH

    		Apoptosis Cancer
    Ara-SH is a Cytarabine mercaptopropionic acid-substituted derivative. Ara-SH is used as the trigger to fabricate a smart Cytarabine and Venetoclax-coloaded nanoparticle (AV-NP) through self-assembly. Ara-SH exhibits remarkable synergistic antileukemia effects in vitro and in vivo .
    Ara-SH
  • HY-14941
    Elacytarabine

    CP 4055

    		 Nucleoside Antimetabolite/Analog Cancer
    Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.
    Elacytarabine
  • HY-107093
    MBC-11

    		Others Cancer
    MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research .
    MBC-11
  • HY-107093B
    MBC-11 triethylamine

    		Apoptosis Cancer
    MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research .
    MBC-11 triethylamine
  • HY-117947
    (R)-OR-S1

    		Others Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: